News

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...
These are the first clinical study results for the drug in a large population of patients with darker skin tones ...
Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...
“Atopic dermatitis, a chronic disease with underlying ... Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that ...
Paris: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent ...
This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than ...